Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
26.79
+0.15 (0.56%)
At close: Apr 28, 2026, 4:00 PM EDT
27.32
+0.53 (1.98%)
After-hours: Apr 28, 2026, 7:17 PM EDT
Genmab Employees
Genmab had 2,973 employees as of December 31, 2025. The number of employees increased by 339 or 12.87% compared to the previous year.
Employees
2,973
Change (1Y)
339
Growth (1Y)
12.87%
Revenue / Employee
$1,251,261
Profits / Employee
$323,915
Market Cap
16.26B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Moderna | 4,700 |
| BioMarin Pharmaceutical | 3,221 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
GMAB News
- 11 days ago - Genmab A/S Share Capital Reduction - GlobeNewsWire
- 14 days ago - Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln - Nasdaq
- 14 days ago - Major Shareholder Announcement - GlobeNewsWire
- 14 days ago - Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026 - Finanz Nachrichten
- 14 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 - GlobeNewsWire
- 14 days ago - Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026 - Wallstreet:Online
- 15 days ago - Genmab (GMAB) Unveils Encouraging Data on New Ovarian Cancer Treatment - GuruFocus
- 15 days ago - Genmab A/S: Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S) in Combination with Bevacizumab in Advanced Ovarian Cancer - Finanz Nachrichten